Pfizer has agreed to a most-favored nation drug pricing deal aimed at aligning U.S. drug prices with those in other developed nations. Under this plan, newly launched Pfizer drugs will be priced on par with international benchmarks, and some medications will be offered at approximately 50% discounts via a direct-to-consumer website called TrumpRX. While this initiative could lower U.S. drug costs, industry experts note manufacturers are simultaneously raising prices overseas to protect revenues. This deal marks the first in a series of anticipated agreements implementing this pricing strategy.